BeOne Medicines
ONC
#542
Rank
HK$364.50 B
Marketcap
HK$3,191
Share price
5.09%
Change (1 day)
24.65%
Change (1 year)
BeOne Medicines formerly known as BeiGene, is a multinational pharmaceutical company engaged in the R&D, commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeOne Medicines (ONC)

EPS in 2023 (TTM): -HK$130.41

According to BeOne Medicines's latest financial reports the company's current EPS (TTM) is HK$46.89. In 2022 the company made an earnings per share (EPS) of -HK$151.89 a decrease over its 2021 EPS that were of -HK$119.27.

EPS history for BeOne Medicines from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$130.41-14.14%
2022-HK$151.8927.35%
2021-HK$119.27-19.96%
2020-HK$149.0120.81%
2019-HK$123.3431.52%
2018-HK$93.78417.57%
2017-HK$18.12-37.16%
2016-HK$28.84158.95%
2015-HK$11.14

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
OPKO Health
OPK
-HK$0.71-101.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-HK$7.45-115.89%๐Ÿ‡บ๐Ÿ‡ธ USA